FBIO
Fortress BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The $205 million PRV monetization, ZYCUBO approval, debt reduction, and potential royalty streams could improve Fortress's financial flexibility and support a re-rating if recurring cash flows become visible.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
No reliable direct peer set, analyst revision data, options data, insider activity, or social coverage is available, limiting confidence in market positioning.
Momentum
83
Value
70
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.65 · Bull $5.00 · Bear $2.30
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.00
Why
Momentum83 · Δ7d +24.9
Value70 · Δ7d -0.2
Sentiment62 · Δ7d -6.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
83
26% active weight
Current posture
7d trendFlat
Δ7d
+24.9
Δ21d
+13.7
Value
70
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+0.0
Sentiment
62
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.6
Δ21d
+59.9
Why this grade
Composite grade A. Momentum 82.5 / Value 69.9 / Sentiment 62.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$111.62M
Beta
1.44
Shares Out
33.22M
P/E (TTM) · Derived
-49.9
P/S (TTM)
2.13
P/FCF (TTM) · Derived
0.93
Rev YoY
+22.1%
EPS YoY
-686.9%
Gross Margin
+59.1%
Op Margin
-100.0%
Net Debt
-$12.17M
Current Ratio
2.86
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology